News

A new, larger designed size of AmnioGraft biologic ocular transplantation graft, AmnioGraft AG-5050 (Bio-Tissue Inc.), is now available for the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis. The graft consists of amniotic membrane to protect, repair, and heal damaged eye surfaces.

The TxCell Scanning Laser Delivery System (Iridex), which allows physicians to deliver laser power in a multi-spot scanning mode, has received FDA 510(k) and CE clearance.

In 99 patients seeking refractive surgery and considered at high risk for colonization with methicillin-resistant Staphylococcus spp, results of nasal and/or ocular cultures were positive in seven patients.

Addition of SensoMotoric Instruments technology adds capabilities in ocular surgery guidance technology to Alcon's existing global cataract portfolio.

Presbia announces that the Presbia Flexivue Microlens implantable corneal inlay for presbyopia is now under active consideration for an IDE.

Data from studies of corneal collagen crosslinking (CXL) for keratoconus and postLASIK ectasia were analyzed to understand quantitative changes in topography.

The LEITR 2012 Eye Ball Gala helps raise approximately $125,000 and showcases the need for ocular advancements and research for the blind and visually impaired.

KalVista Pharmaceuticals has received a £2.4 million grant to accelerate development of an oral plasma kallikrein inhibitor for the treatment of diabetic macular edema.

Focal lamina cribrosa defects were highly correlated with glaucomatous structural and functional damage in an evaluation performed with EDI-OCT.

During this week's meeting of the American Academy of Ophthalmology, several ophthalmic organizations are asking health-care professionals to join them in giving the gift of life by registering as eye, organ, and tissue donors.

Carl Zeiss Meditec introduces new optical coherence tomography platforms that span the full spectrum of multi-modality imaging for glaucoma and retinal disease.

Results from studies of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration can be interpreted in a variety of ways, depending on the baseline bias of the individual.